Drug intelligence / Profile preview

bli-1401

Development stage: Phase 2
Lead developer: ABVC BioPharma
Administration: Oral, Intravenous

Overview

BLI-1401, also known as BLEX 404, is a botanical drug derived from an extract of the Maitake mushroom, with β-glucan identified as a main component. Developed by ABVC BioPharma and its partners, the drug is being investigated for its immunomodulatory and anti-tumor properties. The proposed mechanism involves stimulating both innate and adaptive immunity by activating immune cells such as macrophages, T cells, and natural killer (NK) cells. It has also shown potential to enhance hematopoiesis. Clinical development is underway for several oncology indications, including non-small cell lung cancer, pancreatic cancer, triple-negative breast cancer, and myelodysplastic syndromes.

Brand names: BLI-1401-1BLI1401-1BLI 1401-1
Other names: Maitake mushroom extract

Targets

CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)

Beyond the preview

Go deeper on bli-1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bli-1401.

Explore the full profile